vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $101.1M, roughly 1.8× FORRESTER RESEARCH, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -33.5%, a 32.8% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -6.5%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-4.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 0.5%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
AVNS vs FORR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $101.1M |
| Net Profit | $-1.3M | $-33.9M |
| Gross Margin | 47.5% | 56.7% |
| Operating Margin | 1.4% | -36.6% |
| Net Margin | -0.7% | -33.5% |
| Revenue YoY | 0.7% | -6.5% |
| Net Profit YoY | 99.7% | -7941.4% |
| EPS (diluted) | $-0.02 | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $101.1M | ||
| Q3 25 | $177.8M | $94.3M | ||
| Q2 25 | $175.0M | $111.7M | ||
| Q1 25 | $167.5M | $89.9M | ||
| Q4 24 | $179.6M | $108.0M | ||
| Q3 24 | $170.4M | $102.5M | ||
| Q2 24 | $171.7M | $121.8M | ||
| Q1 24 | $166.1M | $100.1M |
| Q4 25 | $-1.3M | $-33.9M | ||
| Q3 25 | $-1.4M | $-2.1M | ||
| Q2 25 | $-76.8M | $3.9M | ||
| Q1 25 | $6.6M | $-87.3M | ||
| Q4 24 | $-397.3M | $432.0K | ||
| Q3 24 | $4.3M | $-5.8M | ||
| Q2 24 | $1.8M | $6.3M | ||
| Q1 24 | $-900.0K | $-6.7M |
| Q4 25 | 47.5% | 56.7% | ||
| Q3 25 | 48.4% | 60.0% | ||
| Q2 25 | 52.6% | 55.5% | ||
| Q1 25 | 53.6% | 55.9% | ||
| Q4 24 | 54.6% | 58.8% | ||
| Q3 24 | 54.5% | 60.5% | ||
| Q2 24 | 55.7% | 57.3% | ||
| Q1 24 | 57.1% | 54.9% |
| Q4 25 | 1.4% | -36.6% | ||
| Q3 25 | 0.1% | 4.7% | ||
| Q2 25 | -42.6% | 6.2% | ||
| Q1 25 | 6.1% | -97.5% | ||
| Q4 24 | -233.0% | -0.5% | ||
| Q3 24 | 7.0% | -0.7% | ||
| Q2 24 | 3.7% | 9.3% | ||
| Q1 24 | 2.4% | -9.3% |
| Q4 25 | -0.7% | -33.5% | ||
| Q3 25 | -0.8% | -2.3% | ||
| Q2 25 | -43.9% | 3.5% | ||
| Q1 25 | 3.9% | -97.1% | ||
| Q4 24 | -221.2% | 0.4% | ||
| Q3 24 | 2.5% | -5.7% | ||
| Q2 24 | 1.0% | 5.2% | ||
| Q1 24 | -0.5% | -6.7% |
| Q4 25 | $-0.02 | $-1.75 | ||
| Q3 25 | $-0.03 | $-0.11 | ||
| Q2 25 | $-1.66 | $0.20 | ||
| Q1 25 | $0.14 | $-4.62 | ||
| Q4 24 | $-8.64 | $0.02 | ||
| Q3 24 | $0.09 | $-0.30 | ||
| Q2 24 | $0.04 | $0.33 | ||
| Q1 24 | $-0.02 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $63.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $126.5M |
| Total Assets | $1.1B | $404.0M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $63.3M | ||
| Q3 25 | $70.5M | $65.1M | ||
| Q2 25 | $90.3M | $67.8M | ||
| Q1 25 | $97.0M | $75.6M | ||
| Q4 24 | $107.7M | $56.1M | ||
| Q3 24 | $89.0M | $62.8M | ||
| Q2 24 | $92.2M | $58.9M | ||
| Q1 24 | $75.8M | $61.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $126.5M | ||
| Q3 25 | $778.0M | $157.7M | ||
| Q2 25 | $776.3M | $159.5M | ||
| Q1 25 | $839.4M | $147.4M | ||
| Q4 24 | $828.5M | $229.5M | ||
| Q3 24 | $1.2B | $234.3M | ||
| Q2 24 | $1.2B | $237.1M | ||
| Q1 24 | $1.2B | $230.9M |
| Q4 25 | $1.1B | $404.0M | ||
| Q3 25 | $1.1B | $414.2M | ||
| Q2 25 | $1.0B | $436.0M | ||
| Q1 25 | $1.1B | $439.8M | ||
| Q4 24 | $1.2B | $503.9M | ||
| Q3 24 | $1.7B | $505.3M | ||
| Q2 24 | $1.7B | $524.2M | ||
| Q1 24 | $1.7B | $555.7M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-3.2M |
| Free Cash FlowOCF − Capex | $21.3M | $-4.3M |
| FCF MarginFCF / Revenue | 11.8% | -4.2% |
| Capex IntensityCapex / Revenue | 3.8% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-3.2M | ||
| Q3 25 | $14.0M | $1.2M | ||
| Q2 25 | $6.8M | $-3.6M | ||
| Q1 25 | $25.7M | $26.7M | ||
| Q4 24 | $57.9M | $-1.8M | ||
| Q3 24 | $23.0M | $264.0K | ||
| Q2 24 | $27.8M | $-2.9M | ||
| Q1 24 | $-8.0M | $611.0K |
| Q4 25 | $21.3M | $-4.3M | ||
| Q3 25 | $7.0M | $524.0K | ||
| Q2 25 | $-4.2M | $-4.2M | ||
| Q1 25 | $19.0M | $26.1M | ||
| Q4 24 | $53.1M | $-2.5M | ||
| Q3 24 | $20.0M | $-223.0K | ||
| Q2 24 | $21.9M | $-3.7M | ||
| Q1 24 | $-12.1M | $-815.0K |
| Q4 25 | 11.8% | -4.2% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | -2.4% | -3.8% | ||
| Q1 25 | 11.3% | 29.0% | ||
| Q4 24 | 29.6% | -2.3% | ||
| Q3 24 | 11.7% | -0.2% | ||
| Q2 24 | 12.8% | -3.1% | ||
| Q1 24 | -7.3% | -0.8% |
| Q4 25 | 3.8% | 1.1% | ||
| Q3 25 | 3.9% | 0.7% | ||
| Q2 25 | 6.3% | 0.5% | ||
| Q1 25 | 4.0% | 0.7% | ||
| Q4 24 | 2.7% | 0.6% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 3.4% | 0.7% | ||
| Q1 24 | 2.5% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | -0.46× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
